National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 2.2024 last visit: June 23, 2024

Elimova E, Shitara K, Moehler MH, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. J Clin Oncol. 2024;12:4040–4040.

Article  Google Scholar 

Lin D, Nguyen H, Shah R, Qiao Y, Hartman J, Sugarman R. Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. Gastric Cancer. 2023;26:415–424. https://doi.org/10.1007/s10120-023-01372-7.

Tsimafeyeu I, Raskin G. Challenges of FGFR2 Testing in Gastric Cancer. Oncol Rev. 2023;14(17):11790.

Article  Google Scholar 

Gordon A, Johnston E, Lau DK, Starling N. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. Onco Targets Ther. 2022;11(15):1183–96.

Article  Google Scholar 

Tsimafeyeu I, Makhov P, Ovcharenko D, et al. A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models. Immunooncol Technol. 2024;26(23):100725.

Article  Google Scholar 

Wainberg ZA, Enzinger PC, Kang YK, et al. Bemarituzumab in Patients With FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FIGHT): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. Lancet Oncol. 2022;23(11):1430–40.

Article  PubMed  Google Scholar 

Tsimafeyeu I, Statsenko G, Vladimirova L, et al. A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer. Invest New Drugs. 2023;41(2):324–32.

Article  PubMed  Google Scholar 

Raskin GA, Mukhina MS, Kravtsova ED, et al. Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization. Arkh Patol. 2023;85(3):40–5.

Article  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

Article  PubMed  PubMed Central  Google Scholar 

Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(7):1470–91.

Article  PubMed  Google Scholar 

Catenacci DVT, Rasco D, Lee J, et al. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol. 2020;38(21):2418–26.

Article  PubMed  PubMed Central  Google Scholar 

Lewin J, Siu LL. Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince? J Clin Oncol. 2015;33(30):3372–4.

Article  PubMed  Google Scholar 

Tsimafeyeu I, Ludes-Meyers J, Stepanova E, et al. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer. 2016;61:20–8.

Article  PubMed  Google Scholar 

Shimozaki K, Fukuda K, Ooki A, et al. Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis. ESMO Gastrointest Oncol. 2024;5:100072. https://doi.org/10.1016/j.esmogo.2024.100072.

Article  Google Scholar 

Kadono T, Iwasa S, Hirose T, et al. Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis. Cancer Med. 2024;13(12):e7401.

Article  PubMed  PubMed Central  Google Scholar 

Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250–8.

Article  PubMed  Google Scholar 

Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079.

Article  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023;41(6):1200–12.

Article  PubMed  Google Scholar 

Kimura H, Araya T, Yoneda T, et al. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun (Lond). 2019;39(1):78.

Article  PubMed  Google Scholar 

Ksienski D, Truong PT, Wai ES, et al. Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort. Clin Oncol (R Coll Radiol). 2021;33(12):e561–9.

Article  PubMed  Google Scholar 

Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open. 2017;2(3):e000206.

Article  PubMed  PubMed Central  Google Scholar 

Cotes Sanchís A, Gallego J, Hernandez R, et al. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS One. 2020;15(7):e0235848.

Article  PubMed  PubMed Central  Google Scholar